Elevation Oncology, Inc. (NASDAQ: ELEV) was downgraded by analysts at Citigroup Inc. to a "market perform" rating.
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 [Yahoo! Finance]
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology, Inc. (NASDAQ: ELEV) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $1.00 price target on the stock, down previously from $5.00.
Elevation Oncology, Inc. (NASDAQ: ELEV) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.